title: Response of Postoperative and Chronic Uveitic Cystoid Macular Edema to a Dexamethasone-Based Intravitreal Implant (Ozurdex).
abstract: To survey the clinical responses to treatment of chronic postoperative and uveitic cystoid macular edema (CME) with a dexamethasone-based intravitreal implant (Ozurdex(®)).
  
  
  
  This retrospective, interventional case series reports on patients with chronic CME after uncomplicated vitrectomy for epiretinal gliosis or phacoemulsification (group 1: 12 eyes) or secondary to noninfectious endogenous uveitis (group 2: 36 eyes). Central retinal thickness (CRT), best-corrected visual acuity (BCVA, logMAR), and intraocular pressure (IOP) throughout follow-up were gleaned from the medical records.
  
  
  
  In group 1, CRT decreased, compared with baseline, from 519 ± 43 to 297 ± 23 and 356 ± 49 μm by the 1- and 3-month visit (P = 0.02) and to 429 ± 57 μm before reimplantation. In group 2, CRT decreased from 460 ± 31 to 300 ± 21 and 312 ± 26 μm by the 1- and 3-month follow-up, respectively (P = 0.001), and to 373 ± 32 μm before reimplantation. Complete resolution of CME was achieved in 67% and 94% (groups 1 and 2, respectively) by 1 month and in 42% and 80% by 3 months after injection. In group 1, BCVA improved from 0.46 ± 0.08 to 0.27 ± 0.09 and 0.20 ± 0.06 (P = 0.01) by the 1- and 3-month follow-up, respectively, and to 0.32 ± 0.08 before reimplantation. In group 2, BCVA improved from 0.47 ± 0.06 to 0.34 ± 0.09, 0.26 ± 0.07, and 0.29 ± 0.08 (P < 0.05) at 1 and 3 months of follow-up and before reimplantation, respectively. A significant IOP increase was not observed in either group. Mean time to reimplantation of Ozurdex was 6.4 ± 5.7 and 6.6 ± 3.4 months for postoperative and uveitic CME, respectively.
  
  
  
  Ozurdex seems to achieve a sustained effect over up to 6 months in postsurgical and uveitic CME.
authors.affiliation: 1 Berner Augenklinik am Lindenhofspital, Swiss Eye Institute , Bern, Switzerland .|2 University of Bern , Bern, Switzerland .
authors.forename: Justus G
authors.initials: JG
authors.lastname: Garweg
authors.affiliation: 3 Department of Ophthalmology, Clinique de l'oeil , Geneva, Switzerland .
authors.forename: Edoardo
authors.initials: E
authors.lastname: Baglivo
authors.affiliation: 4 Department of Ophthalmology, Stadtspital Triemli , Zürich, Switzerland .
authors.forename: Florentina J
authors.initials: FJ
authors.lastname: Freiberg
authors.affiliation: 4 Department of Ophthalmology, Stadtspital Triemli , Zürich, Switzerland .
authors.forename: Maximilian
authors.initials: M
authors.lastname: Pfau
authors.affiliation: 1 Berner Augenklinik am Lindenhofspital, Swiss Eye Institute , Bern, Switzerland .
authors.forename: Isabel B
authors.initials: IB
authors.lastname: Pfister
authors.affiliation: 4 Department of Ophthalmology, Stadtspital Triemli , Zürich, Switzerland .|5 University of Zurich , Zurich, Switzerland .
authors.forename: Stephan
authors.initials: S
authors.lastname: Michels
authors.affiliation: 1 Berner Augenklinik am Lindenhofspital, Swiss Eye Institute , Bern, Switzerland .
authors.forename: Souska
authors.initials: S
authors.lastname: Zandi
mesh_terms: D000368:Aged; D002908:Chronic Disease; D015331:Cohort Studies; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D004343:Drug Implants / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D058449:Intravitreal Injections; D053208:Kaplan-Meier Estimate; D008269:Macular Edema / Q000188:drug therapy* / Q000601:surgery*; D008875:Middle Aged; D012189:Retrospective Studies; D014605:Uveitis / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D004343:Drug Implants; D003907:Dexamethasone